BioSpace News Archive

Coriolis Pharma, a globally operating service provider for R&D and GMP drug product development, R&D and GMP analytics and sterile drug product manufacturing support, announced the launch of a U.S. entity that allows customers to combine the convenience of a local service with the advantages of international expertise.

Onconic Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for oncology and gastrointestinal disorders, announced the results of its Phase 3 ZERO-1 study of JAQBO at Digestive Disease Week 2024, held in Washington D.C. from May 18-21, 2024.

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, and the Cell and Gene Therapy Catapult, an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, announced a collaboration to demonstrate universal automation of CGT manufacturing.

Veritas will have a prominent presence at the upcoming European Society of Human Genetics Congress 2024, to be held in Berlin from June 1 to 4.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that the TEBE-AM Phase 2/3 clinical trial has been converted into a Phase 3 trial.

Milestone® Pharmaceuticals Inc. announced that the United States Food and Drug Administration accepted the Company’s New Drug Application on May 26, 2024 for CARDAMYST nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia.

Akero Therapeutics, Inc. announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:00 p.m. E.T. in New York, NY.

TScan Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to TSC-100 and TSC-101, the Company’s two lead TCR-T therapy candidates for the treatment of heme malignancies.

Predictive Oncology Inc., a leader in AI-driven drug discovery and biologics, announced that Raymond Vennare, Chief Executive Officer, is scheduled to deliver a company overview presentation at the BIO International Convention 2024, which is being held June 3-6 in San Diego.